Sign inJoin free

Watch / Small Cap

Small cap opportunities with “strategic assets”

22 Apr 20263:18

Small cap opportunities with “strategic assets”

General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.

About this video

Key points:

  • Rotation into “strategic assets” in small caps, especially healthcare and critical minerals

  • EV Health (ASX:EVE) seen as leveraged to potential TGA approval-driven revenue growth

  • European Lithium (ASX:EUR) positioned as a strategic European critical metals play

  • Director and strategic investor buying viewed as confidence indicators in these small caps

John Athanasiou from Red Leaf Securities views the current small cap environment as defined by a shift towards “strategic assets”, particularly healthcare and critical minerals, as investors respond to ongoing geopolitical tensions such as the US–Iran conflict. He points to selective opportunities rather than broad-based buying, arguing that investors should treat these exposures as smaller, high-conviction positions within portfolios.

Athanasiou highlights EV Health (ASX:EVE), a producer of nutrition, health and wellness products with a focus on erectile dysfunction, as one such opportunity. He notes the share price move from $0.02 to $0.03 and points to continued on-market accumulation by a major strategic investor with Therapeutic Goods Administration approval expertise. In his view, successful TGA approval represents a key potential revenue inflection point, though he stresses the stock is thinly traded and more suited to a minor, speculative allocation.

In critical minerals, Athanasiou favours European Lithium (ASX:EUR), citing its European location as strategically important given the region’s push for secure critical metal supply. He notes strong year-to-date performance and ongoing on-market director buying, which he interprets as a sign of confidence and further upside potential, even after a significant run.

More like this

We value your privacy

We use essential cookies to make the site work. Non-essential cookies help us improve the experience. You can accept or reject non-essential cookies. Privacy policy